Sotrovimab News and Research

RSS

WHO experts suggest antiviral drug for patients with non-severe covid-19 at highest risk of hospitalization

The antiviral drug molnupiravir is conditionally recommended for patients with non-severe covid-19 who are at highest risk of hospitalization, says a WHO Guideline Development Group of international experts in The BMJ today.

3 Mar 2022

Molecular characteristics of SARS-CoV-2 variants enabling antibody escape

A new review paper published in PLoS Pathogens discusses the new variants and the structural mechanism underlying antibody-mediated neutralization as well as mutational antibody escape.

21 Feb 2022

The ability of therapeutic monoclonal antibodies to neutralize SARS-CoV-2 Omicron BA.2 variant

Researchers evaluated the neutralizing capacity of the clinically approved mAbs against the SARS-CoV-2 Omicron BA.2 variant.

18 Feb 2022

Research identifies differences between Omicron lineages BA.1 and BA.2

Researchers recently identified another Omicron lineage, called BA.2, that is more contagious than BA.1, the Omicron lineage that sparked the winter surge of coronavirus cases in January 2022.

16 Feb 2022

Study analyzes antigenic properties of SARS-CoV-2 Omicron sublineages

A new study elucidated the antigenic properties of the sublineages of the severe acute respiratory syndrome coronavirus-2 Omicron variant.

14 Feb 2022

Neutralizing antibody ABP-310 found to be highly potent against SARS-CoV-2 variants including Omicron

In a new study, a team of researchers described the efficacy of ABP-310, a neutralizing antibody, against SARS-CoV-2 variants, including Omicron.

10 Feb 2022

Omicron resists antibodies, causes less severe disease than previous SARS-CoV-2variants

In two recent studies, researchers at Washington University School of Medicine in St. Louis found evidence that the omicron variant of the virus that causes COVID-19 causes less severe disease than previous variants — at least in rodents — but that many antibody-based therapies may not be effective against it.

10 Feb 2022

Innate immune processes involved in SARS-CoV-2 recognition and resultant inflammation

A new article reviewed the innate immune detection and signaling pathways that the host uses against SARS-CoV-2.

7 Feb 2022

UK's most vulnerable will soon be able to access second ground-breaking antiviral

Thousands of the country's most vulnerable will be able to access the UK's second ground-breaking antiviral - Pfizer's PF-07321332+ritonavir (Paxlovid) - from Thursday 10 February, the government has announced today.

28 Jan 2022

Study explores vaccine effectiveness against the SARS-CoV-2 Omicron variant in patients receiving hemodialysis

A new study studied the clinical impact of SARS-CoV-2 Omicron infection, and vaccine effectiveness, in patients undergoing in-center hemodialysis (IC-HD).

28 Jan 2022

Exploring receptor-blocking conserved non-neutralizing antibodies for SARS-CoV-2 therapy

In a new study, researchers hypothesized and developed broad-spectrum SARS-CoV-2 inhibitors, ReconnAbs, by modifying the existing non-neutralizing antibodies targeted towards the highly conserved epitopes of the SARS-CoV-2 spike (S) protein combined with a receptor-blocking component.

28 Jan 2022

Study shows monoclonal antibody and antiviral therapy are useful in preventing the severity of SARS-CoV-2 Omicron infection

In a new study, researchers assessed the efficacy of the FDA-approved therapeutic mAbs, as well as to small-molecule antiviral agents against the SARS-CoV-2 Omicron variant in Syrian hamsters.

21 Jan 2022

Patient, beware: Some states still pushing ineffective covid antibody treatments

As the omicron variant completes its sweep across the U.S., states with scarce supplies of monoclonal antibody therapies continue to use two treatments that federal health officials warn no longer work against the highly contagious version of the virus that causes covid-19.

21 Jan 2022

Researchers report isolation of potently neutralizing antibodies against highly transmissible SARS-CoV-2 variants

A recent preprint discusses using a combinatorial phage-display library approach to COVIID-19 antibodies.

18 Jan 2022

WHO's recommendation provides two new options for treating COVID-19

WHO has recommended two new drugs for COVID-19, providing yet more options for treating the disease. The extent to which these medicines will save lives depends on how widely available and affordable they will be.

16 Jan 2022

SARS-CoV-2 Omicron variant's infectivity, vaccine breakthrough, and antibody resistance

A recent study uses an artificial intelligence model to investigate Omicron's mutations and its infectivity, vaccine escape capability, and susceptibility to monoclonal antibodies.

10 Jan 2022

SARS-CoV-2 Delta sublineage AY.4.2 shows no increase in cell entry or antibody evasion

Researchers from Germany, in their recent study published in the journal Cellular & Molecular Immunology, have evaluated the mutations in the S protein of one such SARS-CoV-2 strain, a Delta sublineage AY.4.2, which is currently expanding in the UK, and have found that it neither contains any potential for increased cell entry nor antibody escape.

10 Jan 2022

Sotrovimab News and Research

WHO experts suggest antiviral drug for patients with non-severe covid-19 at highest risk of hospitalization

Molecular characteristics of SARS-CoV-2 variants enabling antibody escape

The ability of therapeutic monoclonal antibodies to neutralize SARS-CoV-2 Omicron BA.2 variant

Research identifies differences between Omicron lineages BA.1 and BA.2

Study analyzes antigenic properties of SARS-CoV-2 Omicron sublineages

Neutralizing antibody ABP-310 found to be highly potent against SARS-CoV-2 variants including Omicron

Omicron resists antibodies, causes less severe disease than previous SARS-CoV-2variants

Innate immune processes involved in SARS-CoV-2 recognition and resultant inflammation

UK's most vulnerable will soon be able to access second ground-breaking antiviral

Study explores vaccine effectiveness against the SARS-CoV-2 Omicron variant in patients receiving hemodialysis

Exploring receptor-blocking conserved non-neutralizing antibodies for SARS-CoV-2 therapy

Study shows monoclonal antibody and antiviral therapy are useful in preventing the severity of SARS-CoV-2 Omicron infection

Patient, beware: Some states still pushing ineffective covid antibody treatments

Researchers report isolation of potently neutralizing antibodies against highly transmissible SARS-CoV-2 variants

WHO's recommendation provides two new options for treating COVID-19

SARS-CoV-2 Omicron variant's infectivity, vaccine breakthrough, and antibody resistance

SARS-CoV-2 Delta sublineage AY.4.2 shows no increase in cell entry or antibody evasion

Bolstering current therapeutic antibody treatments to help fight Omicron infections

Researchers create new monoclonal antibody treatment effective against both Delta and Omicron

Booster dose elicits cross-reactive humoral immunity against SARS-CoV-2 Delta and Omicron variants

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News